PTC Therapeutics to Host R&D Day
PTCTEvent to take place on Dec. 2, 2025 in New York City WARREN, N.J., Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m. EST in New York City. The event will also be webcast....
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTCTWARREN, N.J., Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept. 3 at 8:35 a.m. ET Wells Fargo 2025 Healthcare Conference Thursday, Sept....
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
PTCT– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PTCTNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
PTCTLOS ANGELES--(BUSINESS WIRE)---- $PTCT--PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $74
PTCTB of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68
PTCTBarclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $42
PTCTBaird Maintains Outperform on PTC Therapeutics, Lowers Price Target to $66
PTCTRBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $58
PTCTCantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $112
PTCTCitigroup Upgrades PTC Therapeutics to Neutral, Lowers Price Target to $40
PTCTPTC Therapeutics Raises FY2025 Sales Guidance from $600.00M-$800.00M to $650.00M-$800.00M vs $720.13M Est
PTCTPTC Therapeutics Q1 EPS $10.04, Sales $1.18B
PTCTWhy Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
PTCTPTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales.
Ptc Therapeutics Announces Results From The Phase 2 Pivot-Hd Study of PTC518 In Stage 2 And Stage 3 Huntington's Disease Patients Study Met Its Primary Endpoint of Reduction in Blood Huntingtin Protein Levels At Week 12 And Favorable Safety and Tolerabili
PTCTPTC Therapeutics: CHMP Of EMA Issues Positive Opinion On Marketing Authorization Application For Sephience For Treatment Of Children And Adults Living With Phenylketonuria
PTCTRBC Capital Reiterates Outperform on PTC Therapeutics, Maintains $65 Price Target
PTCTJP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $75
PTCTEuropean Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
PTCTPTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
PTCTPTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.
PTC Therapeutics Announces Phase 3 APHENITY Trial Results: Over 97% Of Subjects Participating In The Phe Tolerance Protocol Of The APHENITY Open-Label Extension Study Demonstrate The Ability To Liberalize Their Diet While On Sepiapterin Treatment, With A
PTCTJP Morgan Maintains Overweight on PTC Therapeutics, Raises Price Target to $78
PTCTB of A Securities Upgrades PTC Therapeutics to Neutral, Raises Price Target to $55
PTCTScotiabank Initiates Coverage On PTC Therapeutics with Sector Perform Rating, Announces Price Target of $55
PTCTMorgan Stanley Assumes PTC Therapeutics at Overweight, Raises Price Target to $70
PTCTJP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $72
PTCTPTC Therapeutics Q4 2024 Adj EPS $(0.85) Misses $(0.66) Estimate, Sales $213.00M Miss $232.44M Estimate
PTCTThe FDA Has Accepted PTC Therapeutics' New Drug Application For Vatiquinone For Children And Adults Living With Friedreich's Ataxia, Under Priority Review And Assigned A Prescription Drug User Fee Act Target Action Date Of August 19
PTCTRBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $63
PTCTCitigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $45
PTCTCantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76
PTCTPTC Therapeutics Submits NDA To FDA For Vatiquinone As Potential First Approved Therapy For Friedreich Ataxia In Children And Adults, Marking Fourth FDA Application In 2024
PTCTJP Morgan Maintains Overweight on PTC Therapeutics, Raises Price Target to $62
PTCTFDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTCTPTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.
Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $45
PTCTReported Earlier, PTC Therapeutics Secures FDA Approval For Brain-Administered Gene Therapy For AADC Deficiency
PTCTEarnings Preview For PTC Therapeutics
PTCTCitigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $26
PTCTJP Morgan Maintains Overweight on PTC Therapeutics, Raises Price Target to $53
PTCTGoldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $32
PTCTPTC Therapeutics Reports The European Commission Asked CHMP To Review Its January Opinion On Renewal Of Marketing Authorization For Translarna
PTCTJefferies Maintains Buy on PTC Therapeutics, Raises Price Target to $46
PTCTEuropean Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
PTCTPTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available in Europe.
PTC Therapeutics Paused 2024 Revenue Guidance as it Struggles to Weigh the Impact of Continued Authorization of Translarna in Europe
PTCTPTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation
PTCTJefferies Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $62
PTCTAnalyst Ratings for PTC Therapeutics
PTCTAnalysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Morgan Stanley Initiates Coverage On PTC Therapeutics with Equal-Weight Rating, Announces Price Target of $54
PTCTPTC Therapeutics Reaffirms FY22 Guidance
PTCT